Renin-angiotensin-aldosterone system polymorphisms and 5-year mortality in survivors of acute myocardial infarction: a report from the Osaka Acute Coronary Insufficiency Study.

This study sought to evaluate whether genetic variants in the renin-angiotensin-aldosterone system (RAAS) have an impact on long-term mortality after acute myocardial infarction (AMI) in the percutaneous coronary intervention (PCI) era. We investigated the impacts of individual and combinations of 4 major RAAS genetic variants, angiotensinogen (AGT) T1311C, angiotensin-converting enzyme (ACE) insertion/deletion (I/D), angiotensin 2 type 1 receptor A1166C, and aldosterone synthase T4660C on 5-year mortality in 3149 post-AMI patients using multivariate Cox regression analysis. The predictive accuracy of all possible RAAS genetic combinations was evaluated using Cox regression analysis, and the best combination that affected prognosis was determined based on the minimal Akaike Information Criterion. There were 220 deaths during a median follow-up of 4.9 years. Independent analyses of any single RAAS variant did not show significant impacts on 5-year mortality. However, analyses in combination revealed that absence of both AGT CC genotype and ACE D allele was associated with lower 5-year mortality (log-rank P = 0.005). Patients with at least either of the AGT CC or ACE D allele had increased mortality with adjusted hazard ratios of 2.07 (95% confidence interval 1.18-3.65, P = 0.012), compared with those with neither the AGT CC nor ACE D allele. Among the 4 RAAS genetic variants examined, a combination of AGT and ACE polymorphisms was associated with 5-year mortality after AMI.

[1]  I. Komuro,et al.  Elevated serum heart-type fatty acid-binding protein in the convalescent stage predicts long-term outcome in patients surviving acute myocardial infarction. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[2]  E. Boersma,et al.  Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association (PERGENE) study , 2011, Netherlands Heart Journal.

[3]  Y. Ohnishi,et al.  Impact of atherosclerosis-related gene polymorphisms on mortality and recurrent events after myocardial infarction. , 2006, Atherosclerosis.

[4]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[5]  V. Cameron,et al.  Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. , 2003, Journal of the American College of Cardiology.

[6]  M. Law,et al.  The underlying risk of death after myocardial infarction in the absence of treatment. , 2002, Archives of internal medicine.

[7]  Yusuke Nakamura,et al.  A high-throughput SNP typing system for genome-wide association studies , 2001, Journal of Human Genetics.

[8]  E. Fleck,et al.  Aldosterone synthase (CYP11B2) -344 C/T polymorphism is associated with left ventricular structure in human arterial hypertension. , 2001, Journal of the American College of Cardiology.

[9]  J. Staessen,et al.  Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease. , 2000, European journal of pharmacology.

[10]  T Kuznetsova,et al.  Antihypertensive treatment modulates the association between the D/I ACE gene polymorphism and left ventricular hypertrophy: a meta-analysis , 2000, Journal of Human Hypertension.

[11]  R. Abbate,et al.  Searching for a better assessment of the individual coronary risk profile. The role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms. , 2000, European heart journal.

[12]  H. Crijns,et al.  Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. , 2000, Hypertension.

[13]  Sarah Parish,et al.  Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls , 1999, The Lancet.

[14]  Y. Yazaki,et al.  Angiotensinogen gene and essential hypertension in the Japanese: extensive association study and meta-analysis on six reported studies. , 1999, Journal of hypertension.

[15]  R H Myers,et al.  Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. , 1998, Circulation.

[16]  T. Ogihara,et al.  Angiotensin II type 1 receptor gene polymorphism is associated with increase of left ventricular mass but not with hypertension. , 1998, American journal of hypertension.

[17]  J. Staessen,et al.  The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular‐renal risk , 1997, Journal of hypertension.

[18]  A. Morice,et al.  Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of and prognosis after myocardial infarction. , 1996, Journal of the American College of Cardiology.

[19]  R Kreutz,et al.  A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. , 1995, The New England journal of medicine.

[20]  P Ducimetière,et al.  Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction , 1994, The Lancet.

[21]  L. Tiret,et al.  Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. , 1994, Hypertension.

[22]  H. Schunkert,et al.  Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. , 1994, The New England journal of medicine.

[23]  Steven C. Hunt,et al.  Molecular basis of human hypertension: Role of angiotensinogen , 1992, Cell.

[24]  Philippe Amouyel,et al.  Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction , 1992, Nature.

[25]  I. Komuro,et al.  Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[26]  I. Komuro,et al.  Low levels of serum n-3 polyunsaturated fatty acids are associated with worse heart failure-free survival in patients after acute myocardial infarction. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[27]  T. Redman.  The Impact of , 1998 .

[28]  H. Akaike,et al.  Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .